# Mynvax Private

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mynvax-private

- Industry: Biotechnology
- Headquarters: Bangalore, India
- Website: www.mynvax.com
- Total disclosed funding: $12M
- Latest round: Series A (Mar 29, 2024)
- Investors on record: 10

## About

Founded in 2017 and based in Karnataka, India, Mynvax Private Limited operates as a clinical-stage vaccine biotechnology company. The company was founded by Gautham Nadig and Raghavan Varadarajan. In May 2024, Mynvax Private Limited raised USD 2.6 million in seed funding led by Inviga and Legacy Assets LLP.

Mynvax develops thermostable vaccines, mainly protein subunit vaccines, to protect against respiratory viral infections and COVID-19. The firm’s lead product is a thermotolerant COVID-19 vaccine formulation.

The company plans to use the funds raised in May 2024 to support the advancement and growth of the company's products.

## Funding rounds

- Series A, Mar 29, 2024, $2.9M — 1Crowd, Legacy Assets LLP, Inviga
- Series A, May 24, 2023, $3.5M — Accel, Kotak Alternate Asset Managers, 1Crowd, LVX, AL trust, Nadig Advisors Private Limited
- Series A, Aug 7, 2021, $4.2M — Accel, Kotak Alternate Asset Managers, Equentia Natural Resources, 1Crowd, LVX, PIL Italica Lifestyle Limited
- Angel, Nov 7, 2018, $1.9M — Kotak Alternate Asset Managers

## Investors

- Kotak Alternate Asset Managers (https://capitalatlas.ai/funds/kotak-alternate-asset-managers) — Angel, Series A
- Accel (https://capitalatlas.ai/funds/accel) — Series A
- Equentia Natural Resources (https://capitalatlas.ai/funds/equentia-natural-resources) — Series A
- 1Crowd (https://capitalatlas.ai/funds/1crowd) — Series A
- LVX (https://capitalatlas.ai/funds/lvx) — Series A
- PIL Italica Lifestyle Limited — Series A
- AL trust — Series A
- Nadig Advisors Private Limited — Series A
- Legacy Assets LLP — Series A
- Inviga (https://capitalatlas.ai/funds/inviga) — Series A